Seregni E, Vellani C, Castellani M R, Maccauro M, Pallotti F, Scaramellini G, Guzzo M, Greco A
Nuclear Medicine Division, Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS-National Cancer Institute, Milan, Italy.
Q J Nucl Med Mol Imaging. 2009 Oct;53(5):513-9.
Thyroid cancer is the most common malignant cancer of the endocrine system. Treatment for well differentiated forms include surgery and radioactive iodine ablation. When cancer cells exhibit a less differentiated phenotype they may no longer be able to accumulate iodine, making 131-I administration ineffective. Recent studies have demonstrated the important role of therapeutic agents that have redifferentiating potential, leading to reactivation and expression of thyrocyte-specific genes, including those responsible for iodine uptake. This review will discuss the results of the most recent studies on drugs with redifferentiating properties and their application in patients with radioiodine refractory thyroid cancer.
甲状腺癌是内分泌系统最常见的恶性肿瘤。分化良好型甲状腺癌的治疗方法包括手术和放射性碘消融。当癌细胞表现出低分化表型时，它们可能不再能够摄取碘，从而使131-I治疗无效。最近的研究表明，具有再分化潜力的治疗药物发挥着重要作用，可导致甲状腺细胞特异性基因的重新激活和表达，包括那些负责碘摄取的基因。本综述将讨论有关具有再分化特性的药物的最新研究结果及其在放射性碘难治性甲状腺癌患者中的应用。
